DBVP Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DBV Technologies S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.61 |
| 52 Week High | €3.61 |
| 52 Week Low | €2.83 |
| Beta | 1.14 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -11.78% |
| 5 Year Change | -88.79% |
| Change since IPO | -57.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| DBVP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 2.2% |
| 1Y | n/a | -17.9% | 8.8% |
Return vs Industry: Insufficient data to determine how DBVP performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how DBVP performed against the UK Market.
Price Volatility
| DBVP volatility | |
|---|---|
| DBVP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: DBVP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DBVP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 88 | Daniel Tassé | www.dbv-technologies.com |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow’s milk protein allergy (CMPA) and eosinophilic esophagitis.
DBV Technologies S.A. Fundamentals Summary
| DBVP fundamental statistics | |
|---|---|
| Market cap | €284.65m |
| Earnings (TTM) | -€92.57m |
| Revenue (TTM) | €4.80m |
59.3x
P/S Ratio-3.1x
P/E RatioIs DBVP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBVP income statement (TTM) | |
|---|---|
| Revenue | US$5.25m |
| Cost of Revenue | US$0 |
| Gross Profit | US$5.25m |
| Other Expenses | US$106.58m |
| Earnings | -US$101.33m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,929.40% |
| Debt/Equity Ratio | 0% |
How did DBVP perform over the long term?
See historical performance and comparison